Cargando…

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

The effect of additional treatments after surgery in patients with primary cardiac sarcoma (PCS) remains unknown. The present study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection. Between October 1979 and December 1995, 15 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Llombart-Cussac, A., Pivot, X., Contesso, G., Rhor-Alvarado, A., Delord, J. P., Spielmann, M., Türsz, T., Le Cesne, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063231/
https://www.ncbi.nlm.nih.gov/pubmed/9862574
_version_ 1782137294434598912
author Llombart-Cussac, A.
Pivot, X.
Contesso, G.
Rhor-Alvarado, A.
Delord, J. P.
Spielmann, M.
Türsz, T.
Le Cesne, A.
author_facet Llombart-Cussac, A.
Pivot, X.
Contesso, G.
Rhor-Alvarado, A.
Delord, J. P.
Spielmann, M.
Türsz, T.
Le Cesne, A.
author_sort Llombart-Cussac, A.
collection PubMed
description The effect of additional treatments after surgery in patients with primary cardiac sarcoma (PCS) remains unknown. The present study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection. Between October 1979 and December 1995, 15 patients with a median age of 45 (range 16-66) and a resected primary cardiac sarcoma [angiosarcoma (six), malignant fibrous histiocytoma (three), leiomyosarcoma (two), rhabdomyosarcoma (two), liposarcoma (one) and synoviosarcoma (one)] received a doxorubicin-containing regimen within 6 weeks of surgery. Adjuvant chemotherapy combinations included cyclophosphamide, vincristine and dacarbazine in four patients; ifosfamide in nine; methotrexate and vincristine in one; and doxorubicin alone in one patient. At present, 13 patients have relapsed (five during therapy), with a median time to progression of 10 months. Twelve patients developed local relapse, in four cases without metastatic disease. Two patients remain in complete remission 27 and 25 months after surgery. The median time to progression was shorter in patients presenting a cardiac angiosarcoma than other histological types (3 vs 14 months, P < 0.01). Twelve patients have died, with a median overall survival of 12 months. The 2-year survival rate is 26%. Survival was significantly longer for patients with completely resected tumours (22 vs 7 months; P = 0.02) and those who did not have angiosarcoma (18 vs 7 months; P = 0.04). In conclusion, post-operative conventional doxorubicin-based chemotherapy failed to modify the natural history of patients with resected cardiac sarcomas. Locoregional failure remains the main problem even after histologically complete resection. New approaches must be tested in patients with primary cardiac sarcoma.
format Text
id pubmed-2063231
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20632312009-09-10 Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Llombart-Cussac, A. Pivot, X. Contesso, G. Rhor-Alvarado, A. Delord, J. P. Spielmann, M. Türsz, T. Le Cesne, A. Br J Cancer Research Article The effect of additional treatments after surgery in patients with primary cardiac sarcoma (PCS) remains unknown. The present study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection. Between October 1979 and December 1995, 15 patients with a median age of 45 (range 16-66) and a resected primary cardiac sarcoma [angiosarcoma (six), malignant fibrous histiocytoma (three), leiomyosarcoma (two), rhabdomyosarcoma (two), liposarcoma (one) and synoviosarcoma (one)] received a doxorubicin-containing regimen within 6 weeks of surgery. Adjuvant chemotherapy combinations included cyclophosphamide, vincristine and dacarbazine in four patients; ifosfamide in nine; methotrexate and vincristine in one; and doxorubicin alone in one patient. At present, 13 patients have relapsed (five during therapy), with a median time to progression of 10 months. Twelve patients developed local relapse, in four cases without metastatic disease. Two patients remain in complete remission 27 and 25 months after surgery. The median time to progression was shorter in patients presenting a cardiac angiosarcoma than other histological types (3 vs 14 months, P < 0.01). Twelve patients have died, with a median overall survival of 12 months. The 2-year survival rate is 26%. Survival was significantly longer for patients with completely resected tumours (22 vs 7 months; P = 0.02) and those who did not have angiosarcoma (18 vs 7 months; P = 0.04). In conclusion, post-operative conventional doxorubicin-based chemotherapy failed to modify the natural history of patients with resected cardiac sarcomas. Locoregional failure remains the main problem even after histologically complete resection. New approaches must be tested in patients with primary cardiac sarcoma. Nature Publishing Group|1 1998-12 /pmc/articles/PMC2063231/ /pubmed/9862574 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Llombart-Cussac, A.
Pivot, X.
Contesso, G.
Rhor-Alvarado, A.
Delord, J. P.
Spielmann, M.
Türsz, T.
Le Cesne, A.
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title_full Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title_fullStr Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title_full_unstemmed Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title_short Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
title_sort adjuvant chemotherapy for primary cardiac sarcomas: the igr experience.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063231/
https://www.ncbi.nlm.nih.gov/pubmed/9862574
work_keys_str_mv AT llombartcussaca adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT pivotx adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT contessog adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT rhoralvaradoa adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT delordjp adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT spielmannm adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT turszt adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience
AT lecesnea adjuvantchemotherapyforprimarycardiacsarcomastheigrexperience